The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
HOME > BUSINESS
BUSINESS
- DSP Completes Construction of New Chemical Research Facility in Osaka
June 6, 2013
- AZ Decides Not to Proceed with Regulatory Filings for Novel Oral RA Treatment Fostamatinib
June 6, 2013
- Nihon Chouzai to Increase Its Subsidiary’s Generic Production Capacity
June 5, 2013
- Takeda Unveils Interim Data from ADCETRIS PI Study in Pediatric Patients
June 5, 2013
- Fujifilm, Dr. Reddy’s Terminate Plan for Joint Venture for Generics
June 5, 2013
- Novartis Pharma to Cut Pay of 9 Top Officials and Suspend Promotion of Ethical Drugs for 5 Days Over Diovan Scandal
June 5, 2013
- Nippon Chemiphar to Outsource Production to Vietnam Next Spring
June 5, 2013
- BMKK, Ono Start Copromotion of Orencia following Lifting of All-Case Surveillance
June 5, 2013
- Four Drug Makers File Their Anticancer Drugs for FOLFIRINOX Therapy for Pancreatic Cancer
June 4, 2013
- Japan Pharma Leaders: Drug Development via GHIT Fund Hoped to Fuel Economic Growth in Developing World
June 4, 2013
- Fujifilm Initiates PI Study of MDS Treatment FF-10501 in Japan
June 4, 2013
- AZ to Assess Possibility of EGFR Mutation Testing via Blood in Japan-Europe Study
June 3, 2013
- Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
- EvaluatePharma Estimates Orphan Drug Market Will Grow to US$127 Billion by 2018
May 31, 2013
- Kyowa Kirin Launches Parkinson’s Disease Treatment Nouriast in Japan
May 31, 2013
- Sawai Aims for All Its New MRs to Pass MR Examination for Fifth Year in a Row
May 31, 2013
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
- Eisai Launches Antiepileptic Treatment Inovelon
May 30, 2013
- Nippon Shinyaku Launches Regtect for Supporting Maintenance of Abstinence in Alcohol-Dependent Patients
May 30, 2013
- Ex-Novartis Employee Attended Key Panel Meetings for Diovan Trial
May 29, 2013
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…